Nisa Investment Advisors LLC raised its holdings in Insulet Co. (NASDAQ:PODD – Free Report) by 1.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,388 shares of the medical instruments supplier’s stock after purchasing an additional 43 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Insulet were worth $1,146,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Sheets Smith Wealth Management lifted its position in Insulet by 37.2% during the 4th quarter. Sheets Smith Wealth Management now owns 1,371 shares of the medical instruments supplier’s stock worth $358,000 after buying an additional 372 shares in the last quarter. Trust Asset Management LLC bought a new position in shares of Insulet in the fourth quarter worth about $211,000. Diversify Wealth Management LLC lifted its position in shares of Insulet by 51.2% during the fourth quarter. Diversify Wealth Management LLC now owns 2,762 shares of the medical instruments supplier’s stock worth $751,000 after purchasing an additional 935 shares in the last quarter. Arkadios Wealth Advisors increased its holdings in shares of Insulet by 59.9% in the fourth quarter. Arkadios Wealth Advisors now owns 2,056 shares of the medical instruments supplier’s stock valued at $537,000 after purchasing an additional 770 shares in the last quarter. Finally, Sax Wealth Advisors LLC increased its holdings in shares of Insulet by 101.3% in the fourth quarter. Sax Wealth Advisors LLC now owns 3,044 shares of the medical instruments supplier’s stock valued at $795,000 after purchasing an additional 1,532 shares in the last quarter.
Wall Street Analyst Weigh In
PODD has been the topic of a number of recent research reports. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Canaccord Genuity Group raised their price target on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. BTIG Research boosted their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James lifted their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Finally, Wells Fargo & Company raised their price objective on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $272.81.
Insider Buying and Selling at Insulet
In other news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.
Insulet Stock Down 1.6 %
Shares of Insulet stock opened at $275.89 on Tuesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $19.35 billion, a P/E ratio of 47.24, a price-to-earnings-growth ratio of 3.50 and a beta of 1.22. The business has a 50-day moving average of $267.55 and a two-hundred day moving average of $236.30. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $282.87.
Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.13. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same quarter in the prior year, the firm earned $0.71 earnings per share. As a group, equities analysts predict that Insulet Co. will post 3.22 EPS for the current year.
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
See Also
- Five stocks we like better than Insulet
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Sizing Up a New Opportunity for NVIDIA Investors
- How Can Investors Benefit From After-Hours Trading
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- High Flyers: 3 Natural Gas Stocks for March 2022
- The 3 Biggest M&A Stock Opportunities for 2025
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.